Physician profile
Val Vallat
NPI 1912011735
$10,971.05
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,608 · 2020: $1,773 · 2021: $1,718 · 2022: $1,993 · 2023: $2,199 · 2024: $1,681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,662 · Education: $217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,662.34 |
| Education | $216.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,278.03 | 2019-2024 | Rinvoq, Skyrizi, Botox |
| Medimetriks Pharmaceuticals, INC. | $1,809.12 | 2019-2024 | Clindacin Etz, Neuac, Neo-Synalar |
| Janssen Biotech, INC. | $1,255.34 | 2019-2024 | Tremfya, Simponi, Simponi Aria |
| Genzyme Corporation | $1,041.67 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $614.11 | 2019-2024 | Ilumya, Winlevi |
| Galderma Laboratories, L.P. | $507.96 | 2019-2024 | Aklief, Oracea, Epsolay |
| Leo Pharma INC. | $468.98 | 2019-2023 | Adbry |
| Hill Dermaceuticals, INC. | $331.62 | 2024 | Tolak |
| Pfizer INC. | $279.04 | 2019-2024 | |
| Amgen INC. | $230.77 | 2020-2023 | Otezla |
| Biofrontera INC. | $205.75 | 2019-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Epi Health, LLC | $184.48 | 2019-2022 | |
| Incyte Corporation | $173.70 | 2021-2024 | Opzelura |
| Lilly USA, LLC | $161.32 | 2020-2023 | Taltz, Olumiant |
| Novartis Pharmaceuticals Corporation | $157.73 | 2022-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $157.61 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $149.17 | 2022-2024 | Sotyktu |
| Almirall LLC | $134.07 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $130.62 | 2020-2024 | Dupixent |
| Mayne Pharma Commercial LLC | $110.13 | 2019-2022 | |
| Dermavant Sciences, INC. | $102.75 | 2023-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $100.25 | 2019-2021 | |
| Dermira, INC. | $76.80 | 2019-2020 | |
| Celgene Corporation | $72.20 | 2019 | |
| Arcutis Biotherapeutics, INC. | $58.68 | 2023-2024 | Zoryve |
| Ucb, INC. | $51.44 | 2019-2023 | Cimzia |
| Organon LLC | $24.73 | 2024 | |
| Journey Medical Corporation | $24.49 | 2022 | |
| Aclaris Therapeutics, INC. | $24.41 | 2019 | |
| Sanofi-Aventis U.S. LLC | $23.36 | 2020 | |
| Sebela Pharmaceuticals INC. | $16.46 | 2019 | |
| Mission Pharmacal Company | $14.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Val Vallat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.